News + Filings Transactions Holdings
|
EcoR1 Capital, LLC
|
|
Changes: All | New | Increased | Decreased | Sold Out |
Portfolio as of: |
Name | Ticker | Class | Shares | Change | Value | Change | % Port | % OS | Hist | Date |
Kymera Therapeutics, Inc.
| KYMR | Common | 0 | -796,093 | 0 | -23,588,236,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
Adicet Bio, Inc.
| ACET | Common | 0 | -3,560,700 | 0 | -20,509,632,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
CHINOOK THERAPEUTICS, INC.
| KDNY | Common | 0 | -445,550 | 0 | -10,314,483,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
Beam Therapeutics Inc.
| BEAM | Common | 0 | -198,591 | 0 | -6,080,856,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
Arcutis Biotherapeutics, Inc.
| ARQT | Common | 0 | -415,322 | 0 | -4,568,542,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
MACROGENICS INC
| MGNX | Common | 0 | -619,192 | 0 | -4,439,607,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
Cullinan Oncology, Inc.
| CGEM | Common | 0 | -246,410 | 0 | -2,520,774,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
Black Diamond Therapeutics, Inc.
| BDTX | Common | 0 | -1,191,094 | 0 | -2,251,168,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
Surface Oncology, Inc.
| SURF | Common | 0 | -3,082,959 | 0 | -2,154,372,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
Erasca, Inc.
| ERAS | Common | 0 | -678,441 | 0 | -2,042,107,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
Eucrates Biomedical Acquisition Corp.
| EUCR | SHS | 0 | -200,000 | 0 | -2,028,000,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
Gracell Biotechnologies Inc.
| GRCL | SPONSORED ADS | 0 | -798,948 | 0 | -1,486,043,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
Eucrates Biomedical Acquisition Corp.
| EUCRW | *W EXP 10/23/202 | 0 | -66,666 | 0 | -675,993,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
SELECTA BIOSCIENCES INC
| SELB | Common | 0 | -200,000 | 0 | -278,000,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
Cyteir Therapeutics, Inc.
| CYT | Common | 0 | -43,823 | 0 | -79,758,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
iTeos Therapeutics, Inc.
| ITOS | Common | 0 | -1,300 | 0 | -17,693,000 | 0.00 | 0.00 |
Hist
| 06/30/2023 |
|
|
|
|